BRISTOL MYERS SQUIBB

🇫🇷France
Ownership
-
Established
1989-01-01
Employees
30K
Market Cap
$97.5B
Website
https://www.bms.com/

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma

Phase 2
Completed
Conditions
First Posted Date
2002-11-22
Last Posted Date
2011-01-28
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00050102
Locations
🇺🇸

Pacific Shores Medical Group, Long Beach, California, United States

🇺🇸

Cancer Institute Medical Group, Santa Monica, California, United States

🇺🇸

Indiana Oncology/ Hematology Consultants, Indianapolis, Indiana, United States

and more 6 locations

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

Phase 3
Completed
Conditions
Interventions
First Posted Date
2002-11-13
Last Posted Date
2011-11-21
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
738
Registration Number
NCT00048581
Locations
🇺🇸

Local Institution, Milwaukee, Wisconsin, United States

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

First Posted Date
2002-11-13
Last Posted Date
2011-12-05
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1250
Registration Number
NCT00048568
Locations
🇺🇸

Local Institution, Milwaukee, Wisconsin, United States

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

First Posted Date
2002-11-13
Last Posted Date
2011-11-24
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1795
Registration Number
NCT00048932
Locations
🇺🇸

Local Institution, Milwaukee, Wisconsin, United States

Atazanavir for HIV Infected Individuals: An Early Access Program

Conditions
First Posted Date
2002-09-30
Last Posted Date
2011-04-14
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00046345
Locations
🇺🇸

LOcal Instituton, Sarasota, Florida, United States

🇵🇷

Local Institution, Rio Piedras, Puerto Rico

🇺🇸

local Institution, Fairfax, Virginia, United States

and more 1 locations

A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine

Phase 3
Completed
Conditions
First Posted Date
2002-05-13
Last Posted Date
2011-04-14
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00036608
Locations
🇺🇸

Local investigator, Dallas, Texas, United States

🇺🇸

Local Investigator, Richmond, Virginia, United States

A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy

Phase 2
Terminated
Conditions
First Posted Date
2002-05-13
Last Posted Date
2010-03-02
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00036621
Locations
🇺🇸

Local Institution, Green Bay, Wisconsin, United States

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen

Phase 3
Completed
Conditions
First Posted Date
2002-05-06
Last Posted Date
2011-04-14
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00035633
Locations
🇺🇸

Local Investigator, Seattle, Washington, United States

🇺🇸

Local Institution, San Francisco, California, United States

🇺🇸

Investigator Meeting, Providence, Rhode Island, United States

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

First Posted Date
2002-05-06
Last Posted Date
2014-01-13
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
230
Registration Number
NCT00035555
Locations
🇺🇸

Medical Univ. of South Carolina, Charleston, South Carolina, United States

🇺🇸

Univ. of Nebraska Medical Center, Omaha, Nebraska, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 9 locations
© Copyright 2024. All Rights Reserved by MedPath